| 09/11/2026 08:30 |
Exegenesis Bio and Modalis Announce Collaboration to Advance MDL-201 for Duchenne Muscular Dystrophy Using EMC181 Muscle-Tropic AAV Capsid |
| 09/10/2026 12:00 |
DMPK Patent Application for DM1 Treatment Allowed in the United States |
| 08/14/2026 11:30 |
(Further Correction) Notice Concerning Corrections to Business and Financial report for Six Months Ended June 30, 2026 |
| 08/14/2026 11:30 |
(Correction) Regarding Corrections to the "Consolidated Financial Results for the Six Months Ended June 30, 2026 [Japanese GAAP]" |
| 08/10/2026 18:40 |
(Correction) Notice Concerning Corrections to Business and Financial report for Six Months Ended June 30, 2026 |
| 08/10/2026 15:30 |
Notice Regarding the Recording of Non-Operating Income and Extraordinary Income |
| 08/10/2026 15:30 |
Business and Financial report for Six Months Ended June 30, 2026 |
| 08/10/2026 15:30 |
Consolidated Financial Results for the Six Months Ended June 30, 2026 [Japanese GAAP] |
| 07/23/2026 08:30 |
Notice of Japanese Patent Allowance Relating to CRISPR-GNDM Technology |
| 07/14/2026 15:30 |
Business Plans and Matters Related to Growth Potential |
| 05/28/2026 12:00 |
Modalis Therapeutics to Present New Preclinical Data for MDL-103 (FSHD) at the FSHD Society 2026 International Research Congress |
| 05/13/2026 15:30 |
Financial Results for the Three Months Ended March 31, 2026 |
| 05/13/2026 15:30 |
Notice Regarding the Recording of Non-Operating Income (Foreign Exchange Income) |
| 05/13/2026 15:30 |
Consolidated Financial Results for the Three Months Ended March 31, 2026 [Japanese GAAP] |
| 04/28/2026 12:00 |
Modalis Therapeutics to Present New Preclinical Data Demonstrating Robust Gene Suppression for MDL-202 and MDL-103 at ASGCT 2026 |
| 04/27/2026 15:45 |
Notice Regarding the Transfer of Fixed Assets at the US Subsidiary and the Recognition of Extraordinary Income |
| 04/14/2026 16:40 |
Notice Regarding Determination of Terms and Conditions of Stock Options (Share Acquisition Rights) |
| 03/26/2026 16:00 |
Notice Regarding Issuance of Stock Options (Share Acquisition Rights) |
| 03/25/2026 15:30 |
Business Plans and Matters Related to High Growth Potential |
| 03/23/2026 08:30 |
Modalis Therapeutics to Present Latest Preclinical Data and Clinical Trial Plans for MDL-101 at the 2026 LAMA2 Conference |
| 03/05/2026 08:00 |
Notice of 2026 Annual General Meeting and Meeting Materials |
| 02/20/2026 15:30 |
Notice regarding partial amendment of the Articles of Incorporation |
| 02/20/2026 15:30 |
Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus |
| 02/12/2026 15:45 |
Notice Regarding the Variance between consolidated results and results of the previous year, non-consolidated results and results of the previous year |
| 02/12/2026 15:45 |
Notice Regarding the Recording of Non-Operating Expense (Foreign Exchange Loss) |
| 02/12/2026 15:45 |
Strategic Development Progress Update for MDL-101: Clinical Readiness Advancement and Program Optimization |
| 02/12/2026 15:45 |
2025 Fiscal Year End Business and Financial report |
| 02/12/2026 15:45 |
Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 [Japanese GAAP] |
| 12/25/2025 13:00 |
Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD |
| 11/13/2025 15:30 |
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration |
| 11/07/2025 15:30 |
Notice Regarding the Recording of Non-Operating Expense (Foreign Exchange Loss) |
| 11/07/2025 15:30 |
Financial Results for the Nine Months Ended September 30, 2025 |
| 11/07/2025 15:30 |
Consolidated Financial Results for the Nine Months Ended September 30, 2025 [Japanese GAAP] |
| 10/01/2025 12:00 |
Notice Regarding Change of the Executive Officer |
